NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has signed a deal to acquire Australian analytical instruments and life science consumables provider Biolab for A$175 million (US $120 million).

Biolab is a division of publicly traded Australian firm Alesco Corp. and has annual revenues of around A$170 million. Thermo Fisher said that it expects to close the transaction on April 30, and that it will integrate the company in to its Laboratory Products and Services Segment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.